NYSE$DOCS
Doximity Inc. · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Doximity reported fiscal Q4 2026 revenue of $145.4M (+5% YoY) with net income of $19.1M and diluted GAAP EPS of $0.10.
For the fourth quarter ended March 31, 2026, Doximity posted revenue of $145.4 million, up 5% year over year, with net income of $19.1 million versus $62.5 million in the prior-year quarter that included larger tax benefits. Diluted GAAP EPS was $0.10; non-GAAP diluted EPS was $0.26. Fiscal 2026 revenue was $644.9 million (+13%). Management guided fiscal Q1 2027 revenue of $151–$152 million and fiscal 2027 revenue of $664–$676 million with adjusted EBITDA of $323–$335 million.
- Q4 revenue $145.4M (+5% YoY); FY26 revenue $644.9M (+13%).
- Q4 net income $19.1M; GAAP EPS $0.10, non-GAAP EPS $0.26.
- FY26 net income $196.1M with strong subscription retention.
- FY27 revenue guide $664M–$676M; Q1 FY27 revenue $151M–$152M.
- AI-powered clinical tools expanding on physician network platform.
Headline financials
Revenue & EPS history
Doximity · Revenue · Quarterly
$145M
Forward guidance
Doximity guided fiscal Q1 2027 revenue of $151–$152 million and adjusted EBITDA of $68.5–$69.5 million. For fiscal 2027 it targets revenue of $664–$676 million and adjusted EBITDA of $323–$335 million.
Tailwinds
- FY27 revenue guide implies continued double-digit growth off FY26 base.
- High physician membership and net revenue retention support visibility.
Headwinds
- Q4 net income fell sharply versus prior-year quarter on lower tax benefits.
- Pharma marketing spend cyclicality can affect quarterly growth rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2026
+5.5%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+3.3%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+45.6%
Q2 2023
Best reaction
-26.6%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.3% | -17.6% | -14.3% | |
| Q3 2026 | -16.8% | -22.1% | -23.9% | |
| Q2 2026 | -13.0% | -18.6% | -26.6% | |
| Q1 2026 | +13.4% | +9.3% | +18.4% | |
| Q4 2025 | -10.1% | -13.2% | -4.3% | |
| Q3 2025 | +36.0% | +29.0% | +9.8% | |
| Q4 2024 | +17.5% | +18.1% | +25.2% | |
| Q3 2024 | +4.3% | +5.9% | +1.9% | |
| Q2 2024 | +13.1% | +20.6% | +16.3% | |
| Q1 2024 | -26.6% | -30.9% | -31.6% | |
| Q4 2023 | -6.4% | -6.2% | -5.2% | |
| Q3 2023 | -14.9% | -11.0% | -22.0% | |
| Q2 2023 | +45.6% | +36.6% | +48.5% | |
| Q1 2023 | -11.1% | -13.1% | -22.2% | |
| Q4 2020 | +3.2% | +4.7% | +22.3% | |
| Q4 2022 | -8.1% | -4.3% | -1.9% | |
| Q3 2021 | +21.1% | +13.9% | -6.8% | |
| Q3 2022 | +27.3% | +16.1% | +2.9% | |
| Q2 2021 | +0.2% | -7.5% | -29.5% | |
| Q2 2022 | +1.4% | +3.4% | -19.1% | |
| Q4 2021 | +8.0% | +7.8% | +44.9% | |
| Q1 2022 | +31.5% | +41.9% | +89.2% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro